Leconte Orthopedics, PLLC

Leconte Orthopedics, PLLC was paid $3.32M by Medicaid between Jan 2018 and Aug 2019, across 64 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 23% of everything it billed.

Compared with peers

Next to other Family Medicine Physician providers in Tennessee

Rank by total paid#19 of 754

Median peer was paid$34K

This provider vs. median98×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	93,412	$2.74M
2019	25,421	$575K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	23%	8,620	6,472	$758K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	22%	36,794	26,917	$733K
J3300	Injection, triamcinolone acetonide, preservative free, 1 mg	18%	4,344	2,964	$606K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	13%	16,191	13,075	$419K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	8.7%	9,188	6,945	$287K
77002		1.5%	2,179	1,473	$50K
20610		1.3%	1,346	906	$42K
72110		1.2%	2,467	2,025	$39K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	1.0%	2,939	2,162	$35K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	1.0%	802	586	$34K
71046	Radiologic examination, chest; 2 views	<1%	2,280	1,838	$26K
64493		<1%	665	379	$21K

52 more codes

85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	3,867	$18K
72050		<1%	1,096	$17K
20605		<1%	525	$14K
20552		<1%	745	$14K
99203	Doctor's office visit, new patient (routine)	<1%	352	$14K
95943		<1%	264	$14K
81025		<1%	3,032	$13K
27096		<1%	53	$12K
82962		<1%	7,809	$11K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	382	$11K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	1,091	$10K
94060		<1%	457	$10K
93000		<1%	1,008	$10K
72070		<1%	854	$10K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	946	$9K
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	980	$8K
95923		<1%	264	$8K
73562		<1%	698	$8K
64494		<1%	665	$7K
64495		<1%	632	$7K
73030		<1%	475	$6K
27370		<1%	55	$4K
45380	Colonoscopy, flexible; with biopsy, single or multiple	<1%	24	$3K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	755	$3K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	17	$2K
73580		<1%	55	$2K
J7321	Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose	<1%	34	$2K
90686		<1%	255	$1K
99308	Subsequent nursing facility care, per day, straightforward	<1%	507	$1K
74019		<1%	92	$1K
76700	Ultrasound, abdominal, real time with image documentation; complete	<1%	51	$1K
90460	Immunization administration through 18 years of age via any route, first or only component	<1%	54	$1K
73521		<1%	64	$1K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	257	$1K
73130		<1%	61	$800.10
73502		<1%	53	$711.54
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	48	$658.28
73610		<1%	67	$636.97
81002		<1%	786	$626.09
J1020	Injection, methylprednisolone acetate, 20 mg	<1%	92	$536.44
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	<1%	18	$498.56
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	843	$450.52
90714		<1%	61	$409.14
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	48	$381.99
85651		<1%	249	$293.22
73522		<1%	30	$230.74
70220		<1%	19	$216.60
82947		<1%	83	$136.90
85610		<1%	77	$135.87
82274		<1%	19	$70.30
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	14	$66.17
99318		0%	35	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialARRINGTON, KELSIE (CREDENTIALING)